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S U M M A R Y
Background: The use of a vancomycin dosing nomogram is an alternative and more cost-effective method
to conventional dosing; it reliably allows the achievement of trough vancomycin serum concentrations
of 5–15 mg/l, with a successful clinical response. Recent guidelines have further recommended that the
trough concentration be maintained at 15–20 mg/l for complicated infections. However, to date no
published nomogram has been constructed to achieve the optimal trough of 15–20 mg/l in an Asian
population. This study aimed to develop two vancomycin nomograms for the achievement of trough
concentrations of 5–15 mg/l and 15–20 mg/l in the Taiwanese population, and to ensure the clinical
efﬁcacy and safety of such nomograms.
Methods: The estimated concentrations and the real concentrations in our patient population were
compared between six pharmacokinetic models to see which was the most precise. As the Ambrose
method was the best at predicting the trough, this was used to create two nomograms, one for a target
trough at 5–15 mg/l and the other for a target trough at 15–20 mg/l. We then evaluated the nomograms
by analyzing the number of patients with the target vancomycin trough concentration, clinical and
microbiological outcomes, and safety.
Results: More patients who had dosing according to the nomogram had a vancomycin trough
concentration within the desired target range than patients who had conventional dosing (65.1% vs.
32.1%, p = 0.001). These patients also had a higher rate of ‘cure’ as the clinical response (35.7% vs. 27.1%)
and ‘eradication’ as the microbiological response (46.4% vs. 29.2%), and a lower rate of nephrotoxicity
(14.3% vs. 22.9%). For the patients with a complicated infection, more had a trough between 15 and
20 mg/l when vancomycin was dosed with the nomogram than when dosed conventionally (41.2% vs.
12.1%, p = 0.019).
Conclusions: We found that when dosing vancomycin with these nomograms, patients tended to have
vancomycin trough concentrations within the target range and also to have a better outcome with regard
to clinical efﬁcacy and the safety proﬁle.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Vancomycin has been an important antibiotic for ﬁghting Gram-
positive bacteria for decades, and has become particularly important
as a result of the worldwide problem of methicillin-resistant
Staphylococcus aureus (MRSA). According to the data of the Taiwan
Center for Disease Control, the proportion of MRSA in all S. aureus§ The pilot data from this study were presented as a poster, ‘‘First vancomycin
dosing nomogram constructed to achieve high trough level’’, at the American
College of Clinical Pharmacy 2010 Spring Practice and Research Forum, Charlotte,
North Carolina, USA, April 23–27, 2010.
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http://dx.doi.org/10.1016/j.ijid.2012.07.005isolated in the intensive care units (ICUs) of medical centers in
Taiwan was 77.4% in 2009.1 At the same time, studies found the
MRSA colonization rate in community settings in Taiwan to be 7.2%
for children2 and 3.8% for adults.3,4 As a result, vancomycin has been
used widely to treat various infectious diseases in Taiwan.
Eliminated primarily via the renal route, vancomycin has
complicated pharmacokinetic characteristics that may be highly
variable among different patients.5 Moreover, as a time-dependent
antibiotic and with AUC/MIC (area under the concentration curve
divided by minimal inhibitory concentration) as the best predictor
of its killing activity, there have been extensive discussions as to
the most effective vancomycin trough levels for maximizing its
killing ability. As a result of reported increasing MIC values for
MRSA, recent guidelines have recommended aiming at a vanco-
mycin serum trough concentration of 15–20 mg/l for complicatedses. Published by Elsevier Ltd. All rights reserved.
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hospital-acquired, health care-associated, or ventilator-associated
pneumonia.6,7 This high trough concentration can improve
penetration and may improve the clinical outcomes of patients
with these complicated infections.
In order to reach this target range of vancomycin trough
concentration, it may not be enough to dose vancomycin following
the traditional dosing method. Although the use of a vancomycin
dosing nomogram has been proven to be more cost-effective than
conventional dosing (15 mg/kg of body weight every 12 h or by
pharmacokinetic equation),8 many nomograms have been proven
to achieve trough vancomycin serum concentrations of only 5–
15 mg/l.9–12 One study from northern America published recently
showed that the use of their nomogram resulted in 80% of their
patient population achieving vancomycin trough concentrations of
13–22 mg/l.13 However, no published nomogram to date has been
constructed to achieve an optimal vancomycin trough concentra-
tion of 15–20 mg/l and to examine its clinical efﬁcacy and safety in
an Asian population. Because vancomycin pharmacokinetic
parameters can vary widely among individuals, it may be
necessary to develop population-speciﬁc dosing methods.
The objectives of this study were to develop two vancomycin
nomograms to achieve vancomycin serum trough concentrations of
5–15 mg/l and 15–20 mg/l, respectively, in a Taiwanese population,
and to ensure the clinical efﬁcacy and safety of these nomograms.
2. Methods
2.1. Nomogram
Various methods have been developed to estimate the pharma-
cokinetic parameters of vancomycin in order to calculate the dosing
of vancomycin,14 and we sought to determine which one best ﬁt our
patient population. We selected six pharmacokinetic models,
including the Matzke, Birt, Ambrose, Burton, revised Burton, and
Bauer methods (Table 1), and retrospectively collected data from
hospital patients who were given vancomycin and who had had at
least one vancomycin concentration measured between July 2008
and September 2009. The data of a total 45 patients, including age,
height, weight, serum creatinine, vancomycin dose and interval, time
of administration, serum vancomycin concentrations, and time of
vancomycin concentration measurement were collected. The
creatinine clearance was calculated using the Cockroft–Gault
formula.
The vancomycin trough concentration was predicted using







where V is the volume of distribution, k is the elimination rate
constant, t0 is the duration of infusion, t is the dosage interval used,
and t is the time when the concentration was measured after the
end of the infusion. The predicted concentration and the realTable 1
Selected pharmacokinetic models
Methods CLvanco 
Matzke method CLvanco (ml/min) = (CLcr  0.689) + 3.66 
Birt method CLvanco (ml/min) = 0.674  CLcr + 13.45 
Ambrose method CLvanco (ml/min) = CLcr 
Burton method CLvanco (ml/min/kg) = ((CLcr (ml/min)  0.0075
Revised Burton method CLvanco (L/h) = CLcr (ml/min)  0.048 
Bauer method CLvanco (ml/min/kg) = (0.695  CLcr (ml/min/kg
CLvanco, vancomycin clearance; CLcr, creatinine clearance; ABW, actual body weight.concentration were then compared to see which method was the
most precise and least biased using the root mean square error
(RMSE), mean absolute error (MAE), and mean error (ME). RMSE and
MAE are both indicators of how close the predicted concentrations
are to the real concentrations. On the other hand, ME is an indicator
of whether the predicted concentrations are higher or lower than the
real concentrations. The closer these three indicators are to zero, the
more precise and the less biased the method is to predict the
vancomycin trough concentration. We found that the Ambrose
method had the smallest RMSE and MAE and was the third least
biased among the six methods; therefore we concluded that the
Ambrose method was the best at predicting the vancomycin trough
concentration in our patient population (Table 2).
By using the Ambrose method, we created two nomograms, one
for a target vancomycin trough concentration at 5–15 mg/l and the
other for a target at 15–20 mg/l (Figure 1). We then proceeded to
test the clinical efﬁcacy and safety of these two nomograms.
2.2. Clinical efﬁcacy and safety
Patients who were treated with vancomycin during the study
period were recruited into the study. Patients were excluded if
they were undergoing dialysis, had a creatinine clearance of less
than 30 ml/min, weighed less than 30 kg, were treated with
vancomycin for less than 3 days, or if they were receiving
concurrent chemotherapy. We compared the patients in group A,
whose vancomycin doses were based on the conventional method
(15 mg/kg of body weight every 12 h or by pharmacokinetic
equation), with the patients in group B, whose vancomycin doses
were based on the two nomograms.
The efﬁcacy of the nomograms was ﬁrst evaluated by the number
of patients with a target vancomycin trough concentration. All
patients with correct vancomycin levels drawn were included at this
stage of the evaluation. At the same time, we also evaluated the
efﬁcacies of the nomograms by patient clinical outcomes and
microbiological outcomes. At this stage, only patients who had
positive MRSA cultures were included, even if they had had no
vancomycin levels drawn. Clinical outcomes were categorized as
cure, which is the resolution of all signs and symptoms of infection
after the discontinuation of vancomycin; improvement, which is an
improvement in signs and symptoms of infection after the
discontinuation of vancomycin; and failure, which includes
progression of infection within 5 days of vancomycin treatment,
death due to infection, or inability to complete treatment.
Microbiological outcomes were categorized as eradication, which
is the absence of the causative microorganisms from the original
infected sites during treatment; indeterminate, which is when data
are unavailable for evaluation due to death or when it is not possible
to obtain culture; and failure, which is when the causative
microorganisms are not eradicated at the original infected sites.
The safety of the nomograms was evaluated by nephrotoxicity.
Nephrotoxicity is deﬁned as an increase in serum creatinine of
0.5 mg/dl at any time during vancomycin treatment, or a decreaseVolume of distribution (V)
V = 0.72 l/kg if CLcr is >60 ml/min
V = 0.89 l/kg if CLcr is 10–60 ml/min
V = 0.9 l/kg if CLcr is <10 ml/min
V = 0.54 l/kg
V (l) = (0.17  [age in years]) + (0.22  [ABW in kg]) + 15
) + 0.04) V = 0.47 l/kg
V = 0.706 l/kg
)) + 0.05 V = 0.7 l/kg
Table 2
Comparisons of the predicted concentrations by six methods with the real
concentrations
Methods RMSE Ranka MAE Ranka ME Ranka
Matzke 11.24 4 9.00 6 3.42 6
Birt 9.38 2 6.83 2 0.98 2
Ambrose 8.59 1 6.37 1 1.33 3
Burton 11.39 5 8.66 4 2.20 4
Burton revised 10.66 3 7.40 3 0.33 1
Bauer 12.51 6 8.94 5 2.72 5
RMSE, root mean square error; MAE, mean absolute error; ME, mean error.
a Rank 1 has the least bias or best precision, and 6 has the most bias and least
precision.
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severe adverse effects during vancomycin treatment were also
recorded during the study.
2.3. Statistical analysis
Data were presented as the mean and standard deviation. The
statistical analysis was conducted using the Chi-square test toFigure 1. Vancomycin nomograms. (A) Vancomycin dosing nomogram trough targeassess differences between patients in group A and patients in




From December 2009 to July 2011, a total of 137 blood samples
were collected at one community hospital in Taiwan to measure
the vancomycin trough concentration (Figure 2). Among these
collected samples, 38 were excluded for being drawn at the wrong
time or for having insufﬁcient patient data to extrapolate patient
trough concentrations, leaving 99 for the analysis.
At the same time, during these 19 months, 1051 patients used
vancomycin at the same hospital; 975 of them were excluded
because they were undergoing dialysis, had creatinine clearance of
less than 30 ml/min, weighed less than 30 kg, were undergoing
chemotherapy at the same time, or used vancomycin for less than 3
days. Forty-eight patients were assigned to group A (conventionalt at 5–15 mg/l; (B) vancomycin dosing nomogram trough target at 15–20 mg/l.
11051 patients used vancomycin during Dece mber 2009 and July 2011 
717 patients exclu ded  due to: 
(1) Underg oing dialysis   
(2) CLcr  <30  ml/min    
(3) Weight  <30 kg   
(4) Che mothe rapy  
(5) Used vancomycin  ≤3 days 
76 patients inclu ded : 
Patients on vancomycin wit h MR SA 
infectio n
334 patients include d 
99 trough concentrati ons  inclu ded:  
Pat ient  trough  co ncentra tion  with  
corr ect  measur ement 
Group A: 
conventional dosing   
(48 p atie nts) 
Trough  target at 
5–15  mg/l:   
17 patient s 
Trough  target at 
15–20  mg/l:   
31 patients
Group  B: 
nomograms dosing   
(28 patients) 
Trough target at 
5–15 mg/l:  
14 patients 




conv entional dosing    
(56 concentrations) 
Trough  ta rget  at  
5–15 mg/ l:   
23 concentrations 
Trough  ta rget  at  
15–20 mg/l:   
33 concentrations
Group B: 
nomogra ms dosing    
(43 concentrations) 
Troug h target at 
5–15 mg/l: 
26 concentrations 
Troug h target at 
15-20 mg/l: 
17 concentrations
Patients excluded d ue to no 
MRSA pathogen isolated 
137 blood samples collected 
Blood samples exclu ded 
due to being drawn at the
wrong time or insu fficient 
patient  data  to  extr apola te 
trough 
Figure 2. Flow chart of patient selection.
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average ages of the two groups were similar (68.4 vs. 64.0 years)
and both groups had more males than females (64.6% vs. 75%; see
Table 3). The indications for vancomycin were similarly distributed
in the two groups. Most patients were on vancomycin for
pneumonia, wound infection, or bacteremia. While the average
duration of hospital stay for group A was 31 days and for group B
was 48 days, a similar rate of ICU stay was observed in the two
groups (37.5% group A vs. 39.3% group B). The mortality rate was
20.8% for group A and 14.3% for group B.
3.2. Pharmacokinetic outcomes
Among the 99 blood samples included, signiﬁcantly more
patients in group B had a vancomycin trough concentration within
the desired target range than patients in group A (65.1% vs. 32.1%, p
= 0.001; see Table 4). In group A, among the 23 patients whose
trough target was at 5–15 mg/l, 14 (60.9%) were within the targetrange; and among the 33 patients whose trough target was at 15–
20 mg/l, four (12.1%) had a trough concentration within the target
range. On the other hand, in group B, among the 26 patients whose
trough target was at 5–15 mg/l, 21 (80.8%, p = 0.124 compared to
group A) were within the target range; and among 17 patients
whose trough target was at 15–20 mg/l, seven of them (41.2%; p =
0.019 compared to group A) had a trough concentration within the
target range.
3.3. Clinical efﬁcacy and safety outcomes
No signiﬁcant differences were found when comparing clinical
outcomes, microbiological outcomes, and safety between the two
groups (Table 5). When looking at clinical outcomes, cure was
observed in 13 patients (27.1%) in group A and 10 patients (35.7%)
in group B, while 14 patients (29.2%) in group A and eight patients
(28.6%) in group B were classiﬁed as failure. Patients in group B had
a slightly higher rate of achieving either cure or improvement than
Table 3
Information for the patients in the two groups
Characteristics Group A (n = 48) Group B (n = 28) Total (n = 76)
Mean  SD age (years) 68.4  18.3 64.0  16.5 -
M/F 31/17 21/7 -
Indication for vancomycin
Pneumonia 25 10 35
CNS infection 0 3 3
Osteomyelitis 3 0 3
Septic shock 2 1 3
Bacteremia 5 3 8
Cellulitis 3 1 4
DM foot 1 0 1
UTI 5 0 5
Wound infection 4 10 14
Number of patients had ICU stay (%) 18 (37.5) 11 (39.3) 29 (38.2)
Duration of hospital stay (days), mean  SD 31  22 48  32 38  28
Number of patients who died (%) 10 (20.8) 4 (14.3) 14 (18.4)
Renal function
Baseline CLcr (ml/min) 96.3 79.3 90.0
Change in SCr (mg/dl), mean  SD 0.27  0.83 a 0.07  0.55 b N/A
SD, standard deviation; M, male; F, female; CNS, central nervous system; DM, diabetes mellitus; UTI, urinary tract infection; ICU, intensive care unit; CLcr, creatinine
clearance; SCr, serum creatinine; N/A, not available.
a Six patients were excluded because no serum creatinine data available after the end of vancomycin therapy.
b Three patients were excluded because no serum creatinine data available after the end of vancomycin therapy.
Table 4
Attainment of target vancomycin trough concentrations
Outcomes Group A Group B p-Value
Total (n = 56) (n = 43)
Concentrations in trough target range, n (%) 18 (32.1%) 28 (65.1%) 0.001
Trough target at 5–15 mg/l (n = 23) (n = 26)
Concentrations in trough target range, n (%) 14 (60.9%) 21 (80.8%) 0.124
Less than target trough range, n (%) 3 (13.0%) 3 (11.5%)
Greater than target trough range, n (%) 6 (26.1%) 2 (7.7%)
Trough target at 15–20 mg/l (n = 33) (n = 17)
Concentrations in trough target range, n (%) 4 (12.1%) 7 (41.2%) 0.019
Less than target trough range, n (%) 24 (72.7%) 6 (35.3%)
Greater than target trough range, n (%) 5 (15.2%) 4 (23.5%)
Table 5
Clinical outcomes, microbiological outcomes, and safety














Clinical outcomes 0.699 0.591 0.869
Cure 13 (27.1%) 10 (35.7%) 6 (35.3%) 6 (42.9%) 7 (22.6%) 4 (28.6%)
Improvement 21 (43.8%) 10 (35.7%) 10 (58.8%) 6 (42.9%) 11 (35.5%) 4 (28.6%)
Failure 14 (29.2%) 8 (28.6%) 1 (5.9%) 2 (14.3%) 13 (41.9%) 6 (42.9%)
Microbiological outcomes 0.237 0.453 0.170
Eradication 14 (29.2%) 13 (46.4%) 2 (11.8%) 4 (28.6%) 11 (35.5%) 9 (64.3%)
Indeterminate 26 (54.2%) 12 (42.9%) 13 (76.5%) 8 (57.1%) 13 (41.9%) 4 (28.6%)
Failure 8 (16.7%) 3 (10.7%) 2 (11.8%) 2 (14.3%) 7 (22.6%) 1 (7.1%)
Safety 0.362 0.027 0.491
Nephrotoxicity 11 (22.9%) 4 (14.3%) 5 (29.4%) 0 (0%) 6 (19.4%) 4 (28.6%)
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ical outcomes, 14 patients (29.2%) in group A and 13 patients (46.4%)
in group B had the result of eradication, while eight patients (16.7%)
in group A and three patients (10.7%) in group B were classiﬁed as
failure. The eradication rate was higher in group B.
With regard to safety, a total of 15 patients experienced
nephrotoxicity; 11 patients were in group A and four were in group
B (22.9% vs. 14.3%, p = 0.362). At baseline, patients in group A had a
higher average creatinine clearance than patients in group B (96.3 ml/
min vs. 79.3 ml/min; see Table 3). However, at the end of 19 months,
patients in group A had a greater change in serum creatinine (average
of 0.27 mg/dl) than patients in group B (average of 0.07 mg/dl).We also separated patients into those with a trough target
of 5–15 mg/dl and those with a trough target of 15–20 mg/dl for
a subgroup analysis (Table 5). For patients with a trough
target of 5–15 mg/dl, no signiﬁcant differences were found in
clinical outcomes and microbiological outcomes. However, no
patients in group B experienced nephrotoxicity, while ﬁve
patients in group A had nephrotoxicity, and this difference
was statistically signiﬁcant (0 vs. 29.4%, p = 0.027). No
statistically signiﬁcant differences were found between the
two groups in the clinical outcomes, microbiological outcomes,
or safety outcomes for patients with a trough target of
15–20 mg/dl.
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In previous studies, using nomograms to dose vancomycin was
proven to result in more patients with targeted vancomycin
concentrations.9,11,13 In the present study, comparing vancomycin
dosed using nomograms with vancomycin dosed in the conven-
tional way, signiﬁcantly more patients had a vancomycin trough
concentration within the target range when dosed by nomograms.
This is the ﬁrst time that a vancomycin nomogram has been
constructed to achieve a trough concentration at the higher target
range of 15–20 mg/l in an Asian population. And signiﬁcantly more
patients had a vancomycin trough concentration within the target
range when vancomycin was dosed by the nomogram for these
patients as well. At the same time, patients whose vancomycin was
dosed by nomogram also had slightly better clinical and
microbiological responses than patients whose vancomycin was
dosed conventionally.
We found that especially in those patients whose target was at
the higher range, more physicians were dosing vancomycin using
the traditional method, which resulted in more patients with lower
vancomycin trough concentrations. Lower vancomycin trough
concentrations in these patients with more complicated infections
may possibly lead to treatment failure. Continued effort is needed
to revisit our nomograms to see if we can make any adjustments so
that more patients achieve targeted vancomycin trough concen-
trations. On the other hand, although the 2009 guidelines from the
American Society of Health-System Pharmacists, the Infectious
Diseases Society of America, and the Society of Infectious Diseases
Pharmacists recommend minimum serum vancomycin trough
concentrations be maintained above 10 mg/l to avoid the
development of resistance,7 we still used the target of 5–15 mg/
l for non-complicated infections. This is because our hospital is
newly opened and the average MIC of vancomycin in the hospital is
lower than MICs reported in the current literature. We will
continue to follow up the resistance patterns in the hospital and
make adjustments to the targets accordingly.
Furthermore, few studies have demonstrated the connection
between dosing vancomycin with nomograms and the patient’s
clinical response or microbiological response. In one study,8 when
comparing dosing vancomycin with the pharmacokinetic method
and with a nomogram, the authors found that both groups of
patients had similar results in clinical response, microbiological
response, and nephrotoxicity. In another study,9 Maeda’s nomo-
gram was compared with a standard dosage regimen for
vancomycin. The authors not only found a signiﬁcant difference
between the ratios of patients who achieved target vancomycin
trough concentrations, they also found a higher clinical response
was obtained with Maeda’s nomogram. In our study, we tried to
prove that using nomograms to dose vancomycin would not only
be effective but also safe, therefore we only included patients with
positive MRSA cultures. The patients in the group where
vancomycin was dosed based on nomograms not only had a
higher rate of showing the clinical response of cure, but also had a
higher rate for the microbiological response of eradication. These
patients also had a slightly higher rate of achieving either cure or
improvement in clinical response. At the same time, they had less
nephrotoxicity compared to the patients whose vancomycin was
dosed conventionally. When looking at the rate of ICU stay and the
total length of hospital stay, it appears that our patients whose
vancomycin was dosed with nomograms were sicker than the
patients in the other group. However, their mortality was lower.
This may be the result of many factors, including patient baseline
conditions, co-morbidities, concurrent drugs, etc. From the
perspectives of the clinical and microbiological responses, thepatients whose vancomycin was dosed with nomograms did have a
slightly better outcome than the others.
When looking at baseline renal function, the patients in the
group where vancomycin was dosed based on nomograms
seemed to have a worse creatinine clearance. One would assume
patients with worse renal function might be predisposed to the
nephrotoxicity of vancomycin. However, fewer patients in this
group experienced nephrotoxicity over the study period.
This also strengthens our faith in dosing vancomycin with
nomograms.
Our study had the limitation of a small sample size. Although
we tried to increase patient numbers by extending the duration to
19 months, it was common for patients receiving vancomycin to
fulﬁll one of the exclusion criteria, such as poor renal function or
receiving concurrent chemotherapy. Therefore we only ended up
recruiting 76 patients into the study. Another limitation of the
study was that we did not include certain patient information, such
as co-morbidities or concurrent therapies, which might also have
confounded the results of the study.
In conclusion, we have developed two easy-to-use vancomycin
nomograms to achieve vancomycin serum trough concentrations
of 5–15 mg/l and 15–20 mg/l in a Taiwanese population. We found
that when dosing vancomycin with these nomograms, patients
tended to have vancomycin trough concentrations within the
target range and also to have better outcomes in the clinical
efﬁcacy and safety proﬁle.
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